SYLATRON Drug Profile

✉ Email this page to a colleague

Summary for Tradename: SYLATRON

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for SYLATRON

Recent Clinical Trials for SYLATRON

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
The Cleveland Clinic	Phase 2
Hoosier Cancer Research Network	Phase 2
Roswell Park Cancer Institute	Phase 2

See all SYLATRON clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for SYLATRON Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for SYLATRON Derived from Company Disclosures

These patents were obtained from company disclosures

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Merck Sharp & Dohme Llc	SYLATRON	peginterferon alfa-2b	For Injection	103949	⤷ Sign Up	2012-03-07	Company disclosures
Merck Sharp & Dohme Llc	SYLATRON	peginterferon alfa-2b	For Injection	103949	⤷ Sign Up	2014-02-25	Company disclosures
Merck Sharp & Dohme Llc	SYLATRON	peginterferon alfa-2b	For Injection	103949	⤷ Sign Up	2003-12-13	Company disclosures
Merck Sharp & Dohme Llc	SYLATRON	peginterferon alfa-2b	For Injection	103949	⤷ Sign Up	2015-11-02	Company disclosures
Merck Sharp & Dohme Llc	SYLATRON	peginterferon alfa-2b	For Injection	103949	⤷ Sign Up	2009-09-11	Company disclosures
Merck Sharp & Dohme Llc	SYLATRON	peginterferon alfa-2b	For Injection	103949	⤷ Sign Up	2013-11-10	Company disclosures
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Patent No.	>Estimated Patent Expiration	>Source

3) Low Certainty: US Patents for SYLATRON Derived from Patent Text Search

These patents were obtained by searching patent claims